Clinical Trial Update: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy [Phase 3]

View source ↗

Summary

Phase 3 study comparing insulin efsitora alfa (LY3209590) with insulin degludec in participants with Type 1 diabetes on multiple daily injections; trial complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin Efsitora Alfa (LY3209590)
• insulin degludec (insulin degludec)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 1 Diabetes, Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2025-06-24